Rapamycin in fibrotic diseases: beneficial or detrimental agent?

Chin Med J (Engl). 2013 Apr;126(7):1364-9.

Authors

Xue-Feng Xu¹, Hua-Ping Dai

Affiliation

¹ Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.

PMID: 23557573

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Fibrosis / drug therapy*
Fibrosis / metabolism
Humans
Immunosuppressive Agents / therapeutic use*
Models, Biological
Sirolimus / therapeutic use*

Substances

Immunosuppressive Agents
Sirolimus